Peptide Proof — Evidence-Based Peptide Intelligence. Independent analysis. No paywall.
Here’s What Happened
Peptide stability testing — the systematic evaluation of how peptide therapeutics degrade under stress conditions — is the most underinvested activity in early peptide development, and the most expensive to fix when done wrong. Common failures include misidentifying degradation products (leading to mis-specified impurity limits), testing under physiologically irrelevant conditions (PBS, pH 7.4, which does not reflect the in vivo environment), and neglecting photostability (ICH Q1B, mandatory for all injectables). Each of these mistakes has resulted in Complete Response Letters, clinical holds, and in several cases, program terminations. Here are the seven most common and costly stability testing errors — and how experienced developers avoid them.
Pitfall 1: Testing Only at pH 7.4
The most common stability testing error is testing exclusively at physiological pH. Peptides encounter a pH gradient in vivo: stomach (pH 1.5–3.5), intestinal lumen (pH 6–7.5), blood (pH 7.35–7.45), endosomal compartments (pH 5–6), and lysosomes (pH 4.5–5.0). A peptide stable at pH 7.4 may degrade rapidly at endosomal pH — a catastrophic finding if discovered after formulation lock. Stability testing should cover pH 1.2 (simulated gastric fluid), pH 4.5 (lysosomal), pH 6.8 (intestinal), and pH 7.4 (plasma) as a minimum panel.
Pitfall 2: Ignoring Light Exposure, also known as ICH Q1B
ICH Q1B photostability testing is mandatory for all injectable drugs, yet peptide developers routinely defer it to late-stage development — and then discover that their peptide contains a photolabile residue (tryptophan, tyrosine, cysteine, methionine) that degrades under ambient light. The fix — amber vials, secondary packaging, light-protected administration sets — is simple but must be specified in the NDA/BLA. Discovering photolability at the pre-approval inspection stage, when the packaging is already designed, can delay approval by 6–12 months.
Pitfall 3: Misidentifying Degradation Products
Peptide degradation generates a complex mixture of structurally related impurities: deamidation products (+1 Da), oxidation products (+16 Da), hydrolysis fragments, diketopiperazine formation, and aggregation products. LC-MS alone is insufficient to distinguish, for example, asparagine deamidation (Asn→Asp, +1 Da) from aspartate isomerization (Asp→isoAsp, same mass). Misidentifying a degradation product leads to incorrect impurity specifications, which the FDA will flag during CMC review. The solution is orthogonal analytical methods: LC-MS for mass identification, LC-MS/MS for sequence localization, and NMR or X-ray crystallography for structural confirmation of major degradation products.
Pitfall 4: Neglecting Excipient Compatibility
Peptide formulations contain excipients — buffers, tonicity agents, preservatives, surfactants — that can react with the peptide. Benzyl alcohol (a common preservative in multi-dose injectables) accelerates deamidation of asparagine residues through a nucleophilic mechanism. Polysorbate 80 (a surfactant to prevent aggregation) can oxidize methionine and cysteine residues through residual peroxide content. Excipient compatibility should be tested before formulation lock, not after stability failures emerge in ICH storage conditions.
Pitfall 5: Using Accelerated Conditions Without Supporting Real-Time Data
ICH Q1A allows 6-month accelerated stability data (40°C/seventy-five percent RH) to support a 2-year shelf life, but this extrapolation is less reliable for peptides than for small molecules. Peptide degradation pathways — especially aggregation — are not Arrhenius-linear: aggregation at 40°C often proceeds through different mechanisms than aggregation at 5°C. A peptide that shows no aggregation at 6 months at 40°C may still form subvisible particles at 12 months at 5°C. The FDA expects real-time (25°C/sixty percent RH) data to confirm accelerated predictions for peptide products, and filing without adequate real-time data is a common CRL trigger.
Pitfall 6: Inadequate Aggregation Characterization
Peptide aggregation — the formation of dimers, oligomers, and subvisible particles — is a leading cause of immunogenicity. The FDA’s 2025 peptide guidance explicitly recommends subvisible particle analysis (light obscuration or micro-flow imaging) for all injectable peptide products. Relying on visual inspection or UV spectroscopy alone is insufficient. Aggregation should be monitored under multiple stress conditions (temperature, agitation, freeze-thaw) and across the intended shelf life.
Pitfall 7: Filing Without Forced Degradation Data
Forced degradation studies — exposing the peptide to extreme pH, temperature, oxidation, and light to deliberately generate degradation products — are not an ICH requirement but are universally expected by FDA CMC reviewers for peptide NDAs. The data serve two purposes: demonstrating that the analytical methods are stability-indicating (capable of separating and quantifying all relevant degradation products), and establishing the degradation pathway to justify the proposed impurity specifications. Filing without forced degradation data is the single most common CMC deficiency in peptide NDAs.
Expert Insight: The Stability Testing Timeline
Experienced peptide developers begin forced degradation studies at the lead optimization stage — before candidate nomination — to identify stability liabilities that can be engineered out (e.g., replacing a photolabile tryptophan with a stable analog). ICH stability studies — long-term, intermediate, accelerated — should begin at least 6 months before IND filing to have 6-month data available for the IND. Companies that defer stability testing to the IND stage routinely find themselves filing with 1-month data and receiving CMC information requests that delay the 30-day review clock. The time to start stability testing is not “when the formulation is final” — it is “as soon as you have a lead candidate.”
Further Reading
[Natural sign-off — one sentence summary of why this matters.]
Last reviewed: June 2026. Peptide Proof Editorial Team.
